Aerovate Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Aerovate Therapeutics's estimated annual revenue is currently $5.6M per year.
- Aerovate Therapeutics's estimated revenue per employee is $215,385
Employee Data
- Aerovate Therapeutics has 26 Employees.
- Aerovate Therapeutics grew their employee count by -42% last year.
Aerovate Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | President & Founder | Reveal Email/Phone |
2 | Chief Medical Officer | Reveal Email/Phone |
3 | CEO | Reveal Email/Phone |
4 | Head Global Supply Chain | Reveal Email/Phone |
5 | EVP, Clinical Development | Reveal Email/Phone |
6 | SVP, Clinical Development | Reveal Email/Phone |
7 | VP, Biometrics | Reveal Email/Phone |
8 | VP Pharmaceutical Development | Reveal Email/Phone |
9 | SVP Development Operations | Reveal Email/Phone |
10 | VP Medical Affairs | Reveal Email/Phone |
Aerovate Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $12.3M | 88 | 13% | N/A | N/A |
#2 | $1.2M | 6 | -54% | N/A | N/A |
#3 | $5.3M | 50 | -26% | $29.3M | N/A |
#4 | $24.7M | 164 | -5% | $45.2M | N/A |
#5 | $4.8M | 61 | 24% | N/A | N/A |
#6 | $77M | 0 | N/A | $866M | N/A |
#7 | $0.3M | 4 | -33% | N/A | N/A |
#8 | $3.9M | 35 | 25% | N/A | N/A |
#9 | $234.6M | 1196 | 10% | N/A | N/A |
#10 | $18.6M | 133 | -16% | $23.3M | N/A |
What Is Aerovate Therapeutics?
Aerovate Therapeutics is a biotechnology company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Aerovate's lead program is a potentially disease modifying drug, AV-101, for people who suffer from pulmonary arterial hypertension (PAH).
keywords:N/A
N/A
Total Funding
26
Number of Employees
$5.6M
Revenue (est)
-42%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Aerovate Therapeutics News
2022-03-30 - Aerovate Therapeutics Announces Full-Year 2021 Financial ...
WALTHAM, Mass., March 30, 2022 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company...
2022-03-30 - Aerovate Therapeutics GAAP EPS of -$1.87 misses by $0.29
Aerovate Therapeutics press release (NASDAQ:AVTE): FY GAAP EPS of -$1.87 misses by $0.29. Cash, cash equivalents and short-term investments...
Other Companies in Boston
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1.8M | 26 | -24% | $1.1M |
#2 | $2.9M | 26 | -7% | N/A |
#3 | $1.8M | 26 | 53% | $81.7M |
#4 | $4.6M | 26 | N/A | N/A |
#5 | $0.5M | 26 | 73% | $8.8M |